TMCI Intrinsic Stock Value – TREACE MEDICAL CONCEPTS Announces FY2023 Q2 Earnings Results for June 30 2023

August 13, 2023

🌥️Earnings Overview

TREACE MEDICAL CONCEPTS ($NASDAQ:TMCI) reported their earnings for FY2023 Q2, which concluded on June 30 2023, on August 8 2023. Their total revenue rose by 40.0% from the same quarter the previous year, totaling USD 42.0 million. Net income was reported at USD -12.3 million, which is an improvement from the -17.2 million reported in FY2022 Q2.

Share Price

The company reported that its stock opened at $20.7 and closed at $20.1, resulting in a 2.9% decrease from the prior closing price of $20.7. This decrease was attributed to gains in Q2, which did not meet Wall Street expectations. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for TMCI. More…

    Total Revenues Net Income Net Margin
    166.97 -42.27 -25.3%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for TMCI. More…

    Operations Investing Financing
    -38.44 -160.77 109.71
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for TMCI. More…

    Total Assets Total Liabilities Book Value Per Share
    249.64 99.68 2.45
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for TMCI are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    53.2% -22.3%
    FCF Margin ROE ROA
    -31.3% -15.1% -9.3%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – TMCI Intrinsic Stock Value

    At GoodWhale, we’ve conducted an analysis of TREACE MEDICAL CONCEPTS’ fundamentals. Our proprietary Valuation Line has estimated that the fair value of TREACE MEDICAL CONCEPTS’ stock is around $29.8. However, currently the stock is being traded at only $20.1, which means the stock is undervalued by 32.5%. We believe this presents significant investment opportunity for investors in the short-term. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The company has a strong product portfolio and a wide geographical presence. The company is facing stiff competition from its rivals Pace Medical Inc, Tenon Medical Inc, and EMvision Medical Devices Ltd.

    – Pace Medical Inc ($OTCPK:PMDL)

    EMvision Medical Devices Ltd is a medical device company that develops, manufactures, and markets non-invasive brain scanning devices. The company’s products include the EMvision Neuro-Monitor, which is used for the detection and monitoring of seizures, and the EMvision Glioma Scanner, which is used for the diagnosis and treatment of brain tumors. The company was founded in 2006 and is headquartered in Sydney, Australia.


    TREACE MEDICAL CONCEPTS released their financial results for second quarter of 2023, showing a 40% increase in revenue compared to the same period in the previous year. Net income was reported as -12.3 million, which is an improvement from the -17.2 million reported the year before. Investors may take this as a sign that the company is making strides towards profitability, which could be a positive indicator of long-term potential. However, investors should continue to monitor TREACE’s financial performance and evaluate the risk-reward ratio before committing any capital.

    Recent Posts

    Leave a Comment